Genelux Corporation Common Stock (GNLX) - Total Assets
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) holds total assets worth $32.37 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Genelux Corporation Common Stock cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Genelux Corporation Common Stock - Total Assets Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's total assets have evolved over time, based on quarterly financial data. See Genelux Corporation Common Stock (GNLX) shareholders funds for net asset value and shareholders' equity analysis.
Genelux Corporation Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Genelux Corporation Common Stock's total assets of $32.37 Million consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genelux Corporation Common Stock (GNLX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genelux Corporation Common Stock's current assets represent 79.5% of total assets in 2025, an increase from 16.8% in 2019.
- Cash Position: Cash and equivalents constituted 28.0% of total assets in 2025, up from 13.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Genelux Corporation Common Stock Competitors by Total Assets
Key competitors of Genelux Corporation Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Genelux Corporation Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.68 | 4.67 | 0.26 |
| Quick Ratio | 3.68 | 4.67 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.48 Million | $28.26 Million | $-4.17 Million |
Genelux Corporation Common Stock - Advanced Valuation Insights
This section examines the relationship between Genelux Corporation Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.08 |
| Latest Market Cap to Assets Ratio | 6.93 |
| Asset Growth Rate (YoY) | -45.2% |
| Total Assets | $19.03 Million |
| Market Capitalization | $131.83 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genelux Corporation Common Stock's assets at a significant premium (6.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Genelux Corporation Common Stock's assets decreased by 45.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual total assets of Genelux Corporation Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.03 Million | -45.19% |
| 2024-12-31 | $34.72 Million | +24.46% |
| 2023-12-31 | $27.89 Million | +404.30% |
| 2022-12-31 | $5.53 Million | -31.93% |
| 2021-12-31 | $8.13 Million | -41.99% |
| 2020-12-31 | $14.01 Million | +326.94% |
| 2019-12-31 | $3.28 Million | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more